5 completed, 1 unknown, 1 withdrawn. 7 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 5, Unknown 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Phase 1 | 1 | Completed 1 |
Follow Hyperlipoproteinemia Type I: new trials by email Literature Review of Hyperlipoproteinemia Type I trials Research Report on Hyperlipoproteinemia Type I
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS) AKCEA-ANGPTL3-LRx - Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency | Phase 2 | Completed | Akcea Therapeutics | 3 | 2017-12-21 | 2021-01-07 |
| Alipogene Tiparvovec for the Treatment of LPLD Patients alipogene tiparvovec, Prednisolone, Cyclosporins - LPL Deficiency | Phase 2 | Withdrawn | UniQure Biopharma B.V. | 2016-10-01 | 2017-08-17 | |
| Orlistat for the Treatment of Type I Hyperlipoproteinemia Orlistat - Hyperlipoproteinemia Type I, Hypertriglyceridemia | Phase 2 | Completed | University of Texas Southwestern Medical Center | 2 | 2015-12-01 | 2023-02-08 |
| Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia CAT-2003, Placebo - Lipoprotein Lipase Deficiency, Familial, Hyperlipoproteinemia Type I | Phase 2 | Completed | Catabasis Pharmaceuticals | 13 | 2014-03-01 | 2016-07-21 |
| Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia LCQ908, Placebo - Hyperlipoproteinemia | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 8 | 2010-05-01 | 2020-12-17 |
| Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects Alipogene Tiparvovec (AMT-011), Human LPL [S447X], mycophenolate mofetil, cyclosporine - Familial Lipoprotein Lipase Deficiency | Phase 2 / Phase 3 | Completed | Amsterdam Molecular Therapeutics | 5 | 2009-02-01 | 2011-09-29 |
| Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X] Alipogene Tiparvovec (AMT-011), Human LPL [S447X], Mycophenolate mofetil, cyclosporine - Familial Lipoprotein Lipase Deficiency | Phase 2 / Phase 3 | Unknown | Amsterdam Molecular Therapeutics | 14 | 2007-08-01 | 2011-09-30 |
Hypertriglyceridemia (3) · Hyperlipoproteinemias (2) · Dyslipidemias (1) · Familial hyperchylomicronemia syndrome (1) · Genetic Diseases, Inborn (1) · Hyperlipidemias (1) · Lipid Metabolism Disorders (1) · Lipid Metabolism, Inborn Errors (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (7) · Nutritional and Metabolic Diseases (7) · Dyslipidemias (6) · Genetic Diseases, Inborn (6) · Hyperlipidemias (6) · Lipid Metabolism Disorders (6) · Lipid Metabolism, Inborn Errors (6) · Metabolic Diseases (6) · Metabolism, Inborn Errors (6) · Hyperlipoproteinemias (5)
Alipogene tiparvovec (3) · Mycophenolic Acid (3) · Cyclosporine (2) · Cyclosporins (1) · IONIS-ANGPTL3-LRx (1) · Methylprednisolone (1) · Methylprednisolone Hemisuccinate (1) · Orlistat (1) · Prednisolone (1) · pradigastat (1) · vupanorsen (1)
Amsterdam Molecular Therapeutics (2) · Akcea Therapeutics (1) · Catabasis Pharmaceuticals (1) · Novartis Pharmaceuticals (1) · UniQure Biopharma B.V. (1) · University of Texas Southwestern Medical Center (1)
Canada (6) · United States (2)
Abhimanyu Garg, MD (1) · Daniel Gaudet, MD, Ph.D. (1)